株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

末梢動脈疾患 (PAD) /末梢血管疾患 (PVD):パイプライン製品の分析

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 264085
出版日 ページ情報 英文 165 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.55円で換算しております。
Back to Top
末梢動脈疾患 (PAD) /末梢血管疾患 (PVD):パイプライン製品の分析 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2017
出版日: 2017年05月16日 ページ情報: 英文 165 Pages
概要

末梢血管疾患 (PVD) は、心臓と脳の外側にある血管 (動脈・静脈) の疾患を指します。歩いたり、階段を上ったりした後に腰・もも・ふくらはぎの痛みを伴う痙攣 (間欠性跛行) 、脚のしびれ・脱力、下腿・足先の冷たさ、足の指の痛み、治癒しない足・脚、成長が遅い足の爪、男性の勃起障害などの症状が見られます。

当レポートでは、末梢動脈疾患 (PAD) /末梢血管疾患 (PVD) に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

末梢動脈疾患 (PAD)/末梢血管疾患 (PVD)の概要

治療薬の開発

  • パイプライン製品の概要
  • 企業別の治療薬
  • 企業で開発中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • AnGes MG Inc
  • AstraZeneca Plc
  • Athera Biotechnologies AB
  • Athersys Inc
  • Bayer AG
  • Betagenon AB
  • BiogenCell Ltd
  • CardioVascular BioTherapeutics Inc
  • Celgene Corp
  • Diffusion Pharmaceuticals Inc
  • Foresee Pharmaceuticals LLC
  • Hemostemix Ltd
  • ID Pharma Co Ltd
  • Juventas Therapeutics Inc
  • LipimetiX Development Inc
  • miRagen Therapeutics Inc
  • Novartis AG
  • Nuo Therapeutics Inc
  • Proteon Therapeutics Inc
  • Recardio GmbH
  • Resverlogix Corp
  • Sigma-Tau SpA
  • Stemedica Cell Technologies Inc
  • Theravasc Inc
  • VESSL Therapeutics Ltd
  • ViroMed Co Ltd
  • Yuyu Pharma Inc

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9301IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2017, provides an overview of the Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline landscape.

Peripheral vascular disease (PVD) refers to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh or calf muscles after activity, such as walking or climbing stairs (intermittent claudication), leg numbness or weakness, coldness in lower leg or foot, especially when compared with the other side, sores on toes, feet or legs that won't heal, slower growth of toenails and erectile dysfunction in men.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 3, 12, 7, 10 and 2 respectively.

Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview
    • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development
    • AnGes MG Inc
    • AstraZeneca Plc
    • Athera Biotechnologies AB
    • Athersys Inc
    • Bayer AG
    • Betagenon AB
    • BiogenCell Ltd
    • CardioVascular BioTherapeutics Inc
    • Celgene Corp
    • Diffusion Pharmaceuticals Inc
    • Foresee Pharmaceuticals LLC
    • Hemostemix Ltd
    • ID Pharma Co Ltd
    • Juventas Therapeutics Inc
    • LipimetiX Development Inc
    • miRagen Therapeutics Inc
    • Novartis AG
    • Nuo Therapeutics Inc
    • Proteon Therapeutics Inc
    • Recardio GmbH
    • Resverlogix Corp
    • Sigma-Tau SpA
    • Stemedica Cell Technologies Inc
    • Theravasc Inc
    • VESSL Therapeutics Ltd
    • ViroMed Co Ltd
    • Yuyu Pharma Inc
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Drug Profiles
    • ACP-01 - Drug Profile
    • AEM-28 - Drug Profile
    • ALD-301 - Drug Profile
    • alprostadil - Drug Profile
    • apabetalone - Drug Profile
    • BAY-1193397 - Drug Profile
    • beperminogene perplasmid - Drug Profile
    • BGC-101 - Drug Profile
    • canakinumab - Drug Profile
    • CVBT-141C - Drug Profile
    • DVC-10101 - Drug Profile
    • ELS-140 - Drug Profile
    • FP-045 - Drug Profile
    • JVS-100 - Drug Profile
    • levocarnitine propionate hydrochloride - Drug Profile
    • MRG-110 - Drug Profile
    • MultiGeneAngio - Drug Profile
    • MultiGeneGraft - Drug Profile
    • O-304 - Drug Profile
    • PC-mAb - Drug Profile
    • PDA-002 - Drug Profile
    • PF-05285401 - Drug Profile
    • REC-03 - Drug Profile
    • Rejuveinix - Drug Profile
    • rivaroxaban - Drug Profile
    • sodium nitrite SR - Drug Profile
    • Stem Cell Therapy for Cardiovascular Disease, Central Nervous System Disorders, Infectious Diseases, Respiratory and Metabolic Disorders - Drug Profile
    • transcrocetinate sodium - Drug Profile
    • TXA-127 - Drug Profile
    • TXA-302 - Drug Profile
    • V-10 - Drug Profile
    • VM-202 - Drug Profile
    • vonapanitase - Drug Profile
    • YY-984 - Drug Profile
    • zibotentan - Drug Profile
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AnGes MG Inc, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AstraZeneca Plc, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Athera Biotechnologies AB, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Athersys Inc, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Bayer AG, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Betagenon AB, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by BiogenCell Ltd, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by CardioVascular BioTherapeutics Inc, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Celgene Corp, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Diffusion Pharmaceuticals Inc, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Foresee Pharmaceuticals LLC, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Hemostemix Ltd, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ID Pharma Co Ltd, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Juventas Therapeutics Inc, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by LipimetiX Development Inc, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by miRagen Therapeutics Inc, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Novartis AG, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Nuo Therapeutics Inc, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Proteon Therapeutics Inc, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Recardio GmbH, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Resverlogix Corp, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Sigma-Tau SpA, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Stemedica Cell Technologies Inc, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Theravasc Inc, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by VESSL Therapeutics Ltd, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ViroMed Co Ltd, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Yuyu Pharma Inc, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top